The new Version 7.2 of GenASIs combines fluorescent and bright-field pathology analysis with Immunohistochemistry (IHC), FISH imaging and analysis as well as karyotyping (including automated metaphase finding) in a single platform.

In addition, the new GenASIs platform includes improved laboratory information system, integration and management tools including detailed audit-trail, backup, recovery and maintenance.

Applied Spectral Imaging CEO Limor Shiposh said, "This new offering is in line with our strategy to offer clinicians and researchers the most advanced, efficient and accurate instruments supporting advancements in computer-aided analysis for personalized medicine, companion diagnostics, cancer research, diagnostic and other pathology and cytogenetic applications."

Applied Spectral Imaging program director Yagil Tzur said the company’s customers have asked for a flexible solution suite supporting fully-automated and interactive imaging and analysis.

"We have listened to our customers and are proud to introduce the GenASIs Version 7.2 platforms including our new Go-Path quantitative IHC analysis platform," Tzur added.